JCO 25th Anniversary Timeline

[1981]		Emil Frei III, Chair, Scientific and Publications Committee, oversees development of new ASCO journal.
[1982]		Grune & Stratton agrees to publish the forthcoming Journal of Clinical Oncology (JCO).
1983		Journal of Clinical Oncology launches. Joseph R. Bertino, MD is first Editor-in-Chief of JCO.
		JCO is approved by the National Library of Medicine to be indexed in Index Medicus (Medline) from volume 1, number 1, the first issue.
		Daniel Bergsagel, MD, George P. Canellos, MD, Samuel Hellman, MD, John C. Marsh, MD, Saul A. Rosenberg, MD, are inaugural Associate Editors.
		JCO's first published words, in an editorial by Dr. Bertino, are "Do we need another journal in the cancer field?" The year ends with the journal publishing 819 pages of Original Research, Editorials, Review Articles, Point-of View articles, and Correspondence. [Link]
1984		JCO has 4,657 subscribers; Dr. Bertino's lead 1984 editorial is titled, "Journal of Clinical Oncology: One Year Old and Growing" [Link]
		Research Highlight: First phase III study published in JCO, "Randomized phase III trial of vinblastine, bleomycin, and cis- dichlorodiammine-platinum versus dacarbazine in malignant melanoma" by Luikart et al. [Link]
1987		The journal's editorial office moves from Yale, New Haven, to Dana-Farber Cancer Institute, Boston.
		The journal's publisher, Grune & Stratton, becomes part of W.B. Saunders, the new publisher of record.
1988		George P. Canellos becomes JCO's second Editor-in-Chief.
		Research Highlight: JCO publishes article that addresses the need for improved pain control in patients with cancer: "Only by changing basic patterns of medical practice, patterns established during the earliest years of medical education, will the problem of inadequate pain treatment be corrected. As clinical oncologists we are in the best position to serve as role models for cancer pain education," writes David Weissman, MD. [Link]
1989		Research Highlight: Study that appears in October issue of JCO about adjuvant treatment of large-bowel cancer leads to large intergroup confirmatory trial. [Link]
1990		Research Highlight: JCO-published research focuses on classes of genes involved in the development of human cancers, including the Li-Fraumeni syndrom: "JCO readers who encounter candidate families are encouraged to refer them to the centers and institutions studying the syndrome," write Judy Garber, MD, and Frederick Li, MD. [Link]
1992		First ASCO Curriculum Guideline is published, "Cancer Pain Assessment and Treatment Curriculum Guidelines." [Link]
		JCO has 14,295 subscribers.
1993		Monthly submission of manuscripts to JCO has more than doubled over the journal's first 10 years.
1994		First ASCO Practice Guideline is published, "American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines" [Link]
1995		Research Highlights: Treatment challenges of non-small-cell lung cancer (NSCLC) are analyzed in JCO: "New chemotherapy regimens for NSCLC are a lot like an Elvis sighting--they frequently create excitement but usually do not last long," write David H. Johnson, MD, and Lawrence H. Einhorn, MD. [Link]
1996		JCO first goes online, with the url www.jcojournal.org.
		"Outcomes of Cancer Treatment for Technology Assessment and Cancer Treatment Guidelines," ASCO's Technology Assessment is published: "In 1993, the Health Services Research Committee of the American Society of Clinical Oncology (ASCO) charged an Outcomes Working Group with defining the outcomes of adult and pediatric cancer treatment to be used for technology assessment and development of cancer treatment guidelines." [Link]
		JCO publishes first ASCO Medical Oncology Workforce study: "There does not appear to be an oversupply of medical oncogists in the United States." [Link]
		Consultant Editor role is created.
1997		"Diagnosis in Oncology" series is launched, Arthur Skarin, MD, Consultant Editor oversees. [Link]
		Biostatistical review is formally incorporated as part of peer review; Colin Begg, PhD, to oversee as Biostatistical Consultant Editor.
		ASCO's first Breast Cancer Surveillance Guidelines are published. [Link]
		Groundbreaking ASCO "Resource Document for Curriculum Development in Cancer Genetics Education" is published; precursor to launch of ASCO Curriculum Series with first title on Cancer Genetics. [Link]
		"Biology of Neoplasia" series is launched, overseen by Stephen A. Cannistra, MD, Associate and Consultant Editor: "The quantum leap in the cure rate will come when we have the technologic means to put these ideas into action in the clinic." [Link]
1998		ASCO's "Training Resource Document for Curriculum Development in Medical Oncology" is published: "Medical oncology is not only one of the youngest subspecialties in internal medicine, but also one of the fastest growing." [Link]
		JCO's impact factor is 8.288.
		Williams & Wilkins is selected to publish JCO effective in 1999.
		Research Highlight: JCO article by Swedish researchers links the overexpression of a particular gene---c-erbB-2---with lower survival for women with breast cancer that spreads to the lymph nodes at the time of diagnosis. [Link]
		An excerpted version of JCO is translated into Spanish and distributed in South America and Spain.
1999		JCO table of contents is published with subject headings for the first time. [Link]
		Research Highlight: Pediatric Oncology Group researchers report in JCO a major treatment advance for acute childhood lymphoblastic leukemia. [Link]
		Editions of JCO in Chinese---selected articles in translation--are published.
		JCO online is available in a searchable, full-text format at www.jco.org.
2000		The journal's editorial office moves from Dana-Farber Cancer Institute, Boston, to ASCO Headquarters, Alexandria, VA.
		"The Art of Oncology: When the Tumor is Not the Target" column is launched, overseen by Consultant Editor Charles Loprinzi, MD: "The new section...is designed to focus and discuss the issues of patient communication, ethical decision making, and symptom control in the management of advanced cancer.... Although discussing these questions will provide some direction for practicing oncologists, it is well understood that there are no easy answers." [Link]
		Articles judged to have immediate implications for clinical practice are made available ahead of print online through JCO's inaugural Early Release program.
2001		Daniel G. Haller, MD becomes JCO's third Editor-in-Chief.
		JCO's impact factor is 8.773.
		Research Highlight: JCO publishes results from a study by the Southwest Oncology Group—the largest randomized trial of early-stage Hodgkin's disease conducted in the U.S. in two decades—that shows that a short course of chemotherapy followed by radiation significantly improves time to disease progression and minimizes toxicity in patients with early-stage Hodgkin's disease. [Link]
		JCO has 24,000 subscribers.
2002		New JCO Editors' Web site launches online.
		Research Highlight: A study by the National Surgical Adjuvant Breast and Bowel Project is published in the journal that shows that radiation therapy, alone or in combination with tamoxifen, can significantly reduce the risk of breast cancer recurrence in the original or opposite breast among women who have undergone lumpectomy for tumors of 1 centimeter or less in diameter. [Link]
		JCO's impact factor is 9.0.
2003		JCO is published by ASCO---"self-published"---ending its history of being produced by a commercial publisher.
		Inaugural edition of selected articles translated into Polish is published; launch of ongoing series.
		Research Highlight: JCO publishes two studies that show that elderly patients can benefit from, and are willing to consider, aggressive treatment for certain types of cancer. These findings underscore the importance of offering the full range of treatment options to patients with cancer, regardless of age. [Link 1] [Link 2]
2004		"JCO will continue to serve as the single most credible, authoritative resource for disseminating significant clinical oncology research," states Dr. Haller. [Link]
		JCO launches the year with new look and feel, inside and out; redesigned cover presents short list of articles "Inside This Issue"
		JCO makes content available for downloading to PDAs.
		ASCO Annual Meeting abstracts published as a JCO supplement for the first time. [Link]
		Manuscripts are now submitted online to the journal; peer review process becomes electronic.
		JCO's impact factor is 10.9, the first time it reaches double-digits.
		JCO and Annals of Oncology jointly publish "Recommendations for a Global Core Curriculum in Medical Oncology". [Link]
2005		JCO Special Series is launched---a new third issue to be published each month, one month a review issue about a disease-specific or modality-specific topic and the next month's issue about translation oncology: "As we put these new issues together for 2005 and the years ahead, we understand the challenge we have accepted--to make JCO required reading for all clinical oncologists," writes Dr. Haller. [Link]
		Inaugural Review Special Series Issue: Cancer Prevention, Scott M. Lippman, MD, Bernard Levin, MD, Guest Editors: "This first edition of the special series of the JCO is an important recognition of the emerging field of cancer prevention." [Link]
		Inaugural Translational Oncology Special Series Issue: Lee M. Ellis, MD, S. Gail Eckhardt, MD, PhD, Guest Editors: "In this first issue of the Journal of Clinical Oncology Molecular Oncology series, the focus is on angiogenesis and its role in the biology and therapy of cancer patients." [Link]
		Cumulative Translational Oncology Glossary launches--a constantly updated resource for all visitors of www.jco.org. [Link]
		"ASCO Core Curriculum Outline" is published: "The following curriculum should be considered as the educational framework for the training of physicians in medical oncology." [Link]
		JCO joins the World Health Organization's Health InterNetwork Access to Research Initiative (HINARI) program, which provides journal access to institutions in developing countries. [Link]
		Dr. Haller writes, "The Editors wish to thank authors for participating in the growth of JCO, not for growth's sake, but for the journal to remain a definitive source of clinical and translational oncology research." [Link]
		Nora Disis, MD, becomes JCO Translational Oncology Series Deputy Editor.
2006		JCO publishes ASCO's Revised Conflict of Interest Policy: "...the statement represents a recognition of the many factors that can influence judgments about clinical research data and a desire to make as much information as possible available to those reviewing the data." [Link]
		JCO requires registration of clinical trials that are reported on in submitted manuscripts.
		JCO's impact factor is 11.810.
		"ASCO-ESMO Consensus Statement on Quality Cancer Care" is published jointly by JCO and the Annals of Oncology. [Link]
2007		Dr. David M. Khayat becomes Deputy Editor of the International Editions of the journal.
		JCO in translation program includes editions in Chinese, Hungarian, Polish, Russian, Spanish, and Turkish.
		Research Highlight: JCO publishes special issue on health care economics in oncology, Neal J. Meropol, MD, Kevin A. Schulman, MD, Guest Editors: “The implications of rising health care costs in general, and cancer care costs in particular are varied and complex. We hope that this issue of the JCO will help prepare the reader to be an active participant in critical policy discussions that impact the providing of cancer care for our patients.” [Link]
		Translational research articles are formally integrated into ongoing issues of the journal: "Over the last few years, JCO has produced a series on translational oncology topics and original papers. The series was received with enthusiasm by our readers, as well as basic and clinical scientists who found JCO an ideal venue for the publication of their work. In acknowledgment of the seamless integration of translational oncology into cancer care, JCO has now integrated the translational oncology series into each issue" Mary L. Disis, MD, JCO Deputy Editor. [Link]
		JCO's impact factor increases to 13.598.

JCO Celebrates 25 Years